| Clinical and immunological features of severe and moderate coronavirus disease 2019 G Chen, DI Wu, W Guo, Y Cao, D Huang, H Wang, T Wang, X Zhang, ... The Journal of clinical investigation 130 (5), 2620-2629, 2020 | 5370 | 2020 |
| Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study T Chen, DI Wu, H Chen, W Yan, D Yang, G Chen, K Ma, D Xu, H Yu, ... bmj 368, 2020 | 4798 | 2020 |
| Longitudinal changes of inflammatory parameters and their correlation with disease severity and outcomes in patients with COVID-19 from Wuhan, China Z Zeng, H Yu, H Chen, W Qi, L Chen, G Chen, W Yan, T Chen, Q Ning, ... Critical Care 24, 1-12, 2020 | 196 | 2020 |
| Roadmap to functional cure of chronic hepatitis B: an expert consensus Q Ning, DI Wu, GQ Wang, H Ren, ZL Gao, P Hu, MF Han, Y Wang, ... Journal of viral hepatitis 26 (10), 1146-1155, 2019 | 83 | 2019 |
| Potential contribution of increased soluble IL-2R to lymphopenia in COVID-19 patients Y Zhang, X Wang, X Li, D Xi, R Mao, X Wu, S Cheng, X Sun, C Yi, Z Ling, ... Cellular & molecular immunology 17 (8), 878-880, 2020 | 60 | 2020 |
| The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication Q Ning, D Wu, X Wang, D Xi, T Chen, G Chen, H Wang, H Lu, M Wang, ... Signal Transduction and Targeted Therapy 7 (1), 57, 2022 | 56 | 2022 |
| Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study D Wu, P Wang, M Han, Y Chen, X Chen, Q Xia, W Yan, X Wan, C Zhu, ... Hepatology international 13, 573-586, 2019 | 40 | 2019 |
| Toward a cure for hepatitis B virus infection: Combination therapy involving viral suppression and immune modulation and long-term outcome D Wu, Q Ning The Journal of infectious diseases 216 (suppl_8), S771-S777, 2017 | 38 | 2017 |
| End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB D Huang, D Wu, P Wang, Y Wang, W Yuan, D Hu, J Hu, Y Wang, R Tao, ... Journal of Hepatology 77 (1), 42-54, 2022 | 36 | 2022 |
| Upregulation of NKG2C+ Natural Killer Cells, TLR-2 Expression on Monocytes and Downregulation of Regulatory T-Cells Influence PEG-IFN Treatment Efficacy in … W Yan, D Wu, X Wang, T Chen, Q Lai, Q Zheng, J Jiang, J Hou, M Han, ... Antiviral Therapy 20 (6), 591-602, 2015 | 33 | 2015 |
| Interferon-induced macrophage-derived exosomes mediate antiviral activity against hepatitis B virus through miR-574-5p W Wu, D Wu, W Yan, Y Wang, J You, X Wan, D Xi, X Luo, M Han, Q Ning The Journal of Infectious Diseases 223 (4), 686-698, 2021 | 30 | 2021 |
| Twelve-month systemic consequences of COVID-19 in patients discharged from hospital: a prospective cohort study in Wuhan, China T Liu, D Wu, W Yan, X Wang, X Zhang, K Ma, H Chen, Z Zeng, Y Qin, ... Clin Infect Dis 14, 14, 2021 | 25 | 2021 |
| An integration of deep viral suppression with sequential immune modulation (cocktail therapy) to restore antiviral capacity: The future of chronic hepatitis B? D Wu, M Han, Q Ning Journal of Hepatology 62 (1), 240-241, 2015 | 14 | 2015 |
| γδ T cells contribute to the outcome of murine fulminant viral hepatitis via effector cytokines TNF-α and IFN-γ D Wu, W Yan, H Wang, D Huang, X Luo, Q Ning Current Medical Science 38, 648-655, 2018 | 10 | 2018 |
| Pegylated Interferon-ɑ (IFN-ɑ) Enhances the Inhibitory Effect of Natural Killer Cells on Regulatory T Cells via IFN-γ in Chronic Hepatitis B W Yuan, D Huang, D Wu, Y Chen, K Ma, M Han, X Luo, W Yan, Q Ning The Journal of Infectious Diseases 224 (11), 1878-1889, 2021 | 8 | 2021 |
| A disparate subset of double-negative T cells contributes to the outcome of murine fulminant viral hepatitis via effector molecule fibrinogen-like protein 2 D Wu, H Wang, W Yan, T Chen, M Wang, M Han, Z Wu, X Wang, G Ai, ... Immunologic research 64, 518-530, 2016 | 6 | 2016 |
| The potential immune regulation benefit of CpAMs beyond HBV suppression D Wu, W Yan, M Han, Q Ning The Lancet Gastroenterology & Hepatology 6 (9), 680-682, 2021 | 5 | 2021 |
| Hepatitis B virus surface protein-induced hPIAS1 transcription requires TAL1, E47, MYOG, NFI, and MAPK signal pathways H Wang, D Wu, X Wang, G Chen, Y Zhang, W Yan, X Luo, M Han, Q Ning Biological Chemistry 397 (11), 1173-1185, 2016 | 5 | 2016 |
| Insufficient immunity led to virologic breakthrough in NAs-treated chronic hepatitis B patients switching to Peg–IFN–ɑ D Huang, W Yan, M Han, W Yuan, P Wang, Y Chen, X Wan, X Luo, D Wu, ... Antiviral Research 197, 105220, 2022 | 3 | 2022 |
| New strategies for clinical cure and Institute of hepatitis B: viral suppression combined with immune modulation and its road map W Di, H Da, N Qin 临床肝胆病杂志 34 (5), 919-925, 2018 | 2 | 2018 |
